Publications by authors named "Sander Brooks"

Claim this Profile
D
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator.
Clemens Muehlan, Sander Brooks, Cedric Vaillant, Michael Meinel, Gabriël E Jacobs

Clin Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement.
Michelle L Mellion, Lucienne Ronco, Cecile L Berends, Lisa Pagan, Sander Brooks

Br J Clin Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.
Benjamin Berger, Sander Brooks, Rob Zuiker, Muriel Richard, Clemens Muehlan

CNS Drugs· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans.
Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar, Philip L Johnson, Brian Lord, Sander Brooks

Transl Psychiatry· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.
Clemens Muehlan, Margaux Boehler, Sander Brooks, Rob Zuiker, Joop van Gerven

J Psychopharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.
Clemens Muehlan, Sander Brooks, Rob Zuiker, Joop van Gerven, Jasper Dingemanse

Eur Neuropsychopharmacol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
Sander Brooks, Gabriël E Jacobs, Peter de Boer, Justine M Kent, Luc Van Nueten

J Psychopharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin.
Henriëtte S de Bruijn, Sander Brooks, Angélique van der Ploeg-van den Heuvel, Timo L M Ten Hagen, Ellen R M de Haas

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sources of variability in the quantification of tissue optical properties by multidiameter single-fiber reflectance and fluorescence spectroscopy.
Sander Brooks, Christopher L Hoy, Arjen Amelink, Dominic J Robinson, Tamar E Nijsten

J Biomed Opt· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis